RU2008141076A - APPLICATION OF THERAPEUTIC HUMAN ALBUMIN FOR THE PRODUCTION OF A MEDICINE FOR THE TREATMENT OF PATIENTS AFFECTING COGNITIVE DISORDERS - Google Patents
APPLICATION OF THERAPEUTIC HUMAN ALBUMIN FOR THE PRODUCTION OF A MEDICINE FOR THE TREATMENT OF PATIENTS AFFECTING COGNITIVE DISORDERS Download PDFInfo
- Publication number
- RU2008141076A RU2008141076A RU2008141076/14A RU2008141076A RU2008141076A RU 2008141076 A RU2008141076 A RU 2008141076A RU 2008141076/14 A RU2008141076/14 A RU 2008141076/14A RU 2008141076 A RU2008141076 A RU 2008141076A RU 2008141076 A RU2008141076 A RU 2008141076A
- Authority
- RU
- Russia
- Prior art keywords
- use according
- albumin
- treatment
- cognitive disorders
- human albumin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
1. Применение человеческого альбумина для изготовления лекарственного средства для лечения пациентов, страдающих когнитивными расстройствами или обладающих риском их развития, независимо от содержания Аβ в крови пациента. ! 2. Применение по п.1, при котором это лекарственное средство находится в форме раствора для плазмафильтрации. ! 3. Применение по п.1, при котором это лекарственное средство находится в форме раствора для внутривенного применения. ! 4. Применение по п.1, при котором альбумин исходно имеет концентрацию от 4% (мас./об.) до 25% (мас./об.). ! 5. Применение по п.4, при котором применяемый альбумин имеет концентрацию от 4,5% (мас./об.) до 5,5% (мас./об.). ! 6. Применение по п.1, при котором применяемый альбумин обладает лучшей связывающей способностью по сравнению с терапевтическим препаратом альбумина, изготовленным в соответствии с Европейской Фармакопеей. ! 7. Применение по любому из пп.1-6, при котором когнитивное расстройство представляет собой болезнь Альцгеймера. 1. The use of human albumin for the manufacture of a medicament for the treatment of patients suffering from cognitive disorders or at risk of their development, regardless of the content of Aβ in the blood of the patient. ! 2. The use according to claim 1, wherein the drug is in the form of a plasma filtration solution. ! 3. The use according to claim 1, in which this drug is in the form of a solution for intravenous use. ! 4. The use according to claim 1, wherein the albumin initially has a concentration of from 4% (w / v) to 25% (w / v). ! 5. The use according to claim 4, in which the used albumin has a concentration of from 4.5% (wt./about.) To 5.5% (wt./about.). ! 6. The use according to claim 1, in which the used albumin has better binding ability compared to a therapeutic albumin preparation made in accordance with the European Pharmacopoeia. ! 7. The use according to any one of claims 1 to 6, in which the cognitive disorder is Alzheimer's disease.
Claims (7)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200702831 | 2007-10-26 | ||
| ES200702831A ES2332846B1 (en) | 2007-10-26 | 2007-10-26 | USE OF THERAPEUTIC HUMAN ALBUMIN FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS AFFECTED BY COGNITIVE DISORDERS. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008141076A true RU2008141076A (en) | 2010-04-27 |
| RU2414925C2 RU2414925C2 (en) | 2011-03-27 |
Family
ID=40583637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008141076/15A RU2414925C2 (en) | 2007-10-26 | 2008-10-17 | Application of therapeutic human albumin for preparing drug for treating patients suffering cognitive disorders |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7851446B2 (en) |
| EP (1) | EP2111868B1 (en) |
| JP (1) | JP5437619B2 (en) |
| CN (1) | CN101417123B (en) |
| AR (1) | AR068901A1 (en) |
| AU (1) | AU2008233025B8 (en) |
| BR (1) | BRPI0804623B8 (en) |
| CA (1) | CA2641830C (en) |
| CL (1) | CL2008003133A1 (en) |
| ES (2) | ES2332846B1 (en) |
| HK (1) | HK1126689A1 (en) |
| MX (1) | MX2008013635A (en) |
| NZ (1) | NZ572131A (en) |
| PL (1) | PL2111868T3 (en) |
| PT (1) | PT2111868E (en) |
| RU (1) | RU2414925C2 (en) |
| UY (1) | UY31418A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10112000B2 (en) | 2010-07-08 | 2018-10-30 | Asahi Kasei Medical Co., Ltd. | Method for reducing amyloid beta concentration in blood |
| CA3033051A1 (en) * | 2016-08-18 | 2018-02-22 | Alkahest, Inc. | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
| US10525107B2 (en) | 2016-08-18 | 2020-01-07 | Alkahest, Inc. | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
| US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| MA48480A (en) | 2017-04-26 | 2020-03-04 | Alkahest Inc | DOSAGE SCHEDULE FOR THE TREATMENT OF COGNITIVE AND MOTOR DEFICIENCIES WITH BLOOD PLASMA AND BLOOD PLASMA PRODUCTS |
| EP3823636A4 (en) * | 2018-07-20 | 2022-04-13 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| EP3643319A1 (en) * | 2018-10-25 | 2020-04-29 | Grifols Worldwide Operations Limited | Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages |
| EP3870190A4 (en) | 2018-10-26 | 2022-09-07 | Alkahest, Inc. | Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery |
| UY39742A (en) * | 2021-04-30 | 2022-11-30 | Grifols Worldwide Operations Ltd | USE OF THERAPEUTIC PLASMA EXCHANGE AND LOW VOLUME PLASMA EXCHANGE FOR TREATMENT * |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3612137A1 (en) * | 1986-04-10 | 1987-10-15 | Biotest Pharma Gmbh | STERILE PLASMA REPLACEMENT |
| US5112298A (en) | 1990-06-25 | 1992-05-12 | Baxter International Inc. | Apheresis method and device |
| US5178603A (en) | 1990-07-24 | 1993-01-12 | Baxter International, Inc. | Blood extraction and reinfusion flow control system and method |
| US6627151B1 (en) * | 1997-06-13 | 2003-09-30 | Helmut Borberg | Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion |
| EP1290451B1 (en) | 2000-05-23 | 2005-12-07 | University Of Southern California | Diagnosis of alzheimer's disease using ldl receptor protein-1 |
| WO2002078670A1 (en) * | 2001-03-02 | 2002-10-10 | Neuron Therapeutics, Inc. | Neuroprotectants formulations and methods |
| AU2002366355A1 (en) | 2001-12-17 | 2003-06-30 | New York State Office Of Mental Health | SEQUESTRATION OF ABeta IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES |
| BR0315008A (en) | 2002-10-04 | 2005-08-09 | Prana Biotechnology Ltd | Neurologically Active Compounds |
| WO2004056318A2 (en) * | 2002-12-19 | 2004-07-08 | New York University | Method for treating amyloid disease |
| ES2285427T3 (en) | 2003-02-13 | 2007-11-16 | Octapharma Ag | PROCEDURE FOR PREPARATION OF AN ALBUMIN SOLUTION. |
| US20050042284A1 (en) | 2003-07-11 | 2005-02-24 | Myriad Genetics, Incorporated | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease |
| AT413336B (en) * | 2003-09-12 | 2006-02-15 | Mattner Frank Dr | APHERESIS DEVICE |
| US20050182044A1 (en) | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
| AT500483B1 (en) | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Kit for prevention or treatment of Alzheimer's disease comprises means for inducing sequestration of amyloid beta in plasma and apheresis apparatus which exhibits an amyloid beta precursor protein receptor |
| US7436304B1 (en) | 2005-07-19 | 2008-10-14 | Visible Assets, Inc | Evidence tracking |
-
2007
- 2007-10-26 ES ES200702831A patent/ES2332846B1/en not_active Expired - Fee Related
-
2008
- 2008-10-17 AR ARP080104523A patent/AR068901A1/en unknown
- 2008-10-17 NZ NZ572131A patent/NZ572131A/en unknown
- 2008-10-17 RU RU2008141076/15A patent/RU2414925C2/en active
- 2008-10-22 EP EP08380301.5A patent/EP2111868B1/en active Active
- 2008-10-22 PL PL08380301T patent/PL2111868T3/en unknown
- 2008-10-22 ES ES08380301T patent/ES2428698T3/en active Active
- 2008-10-22 PT PT83803015T patent/PT2111868E/en unknown
- 2008-10-23 UY UY31418A patent/UY31418A1/en not_active Application Discontinuation
- 2008-10-23 BR BRPI0804623A patent/BRPI0804623B8/en active IP Right Grant
- 2008-10-23 CL CL2008003133A patent/CL2008003133A1/en unknown
- 2008-10-23 MX MX2008013635A patent/MX2008013635A/en active IP Right Grant
- 2008-10-23 CN CN2008101705786A patent/CN101417123B/en active Active
- 2008-10-24 CA CA2641830A patent/CA2641830C/en active Active
- 2008-10-24 AU AU2008233025A patent/AU2008233025B8/en active Active
- 2008-10-24 US US12/257,814 patent/US7851446B2/en active Active
- 2008-10-24 JP JP2008274076A patent/JP5437619B2/en active Active
-
2009
- 2009-07-02 HK HK09105923.2A patent/HK1126689A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0804623A2 (en) | 2009-06-30 |
| AU2008233025B2 (en) | 2013-06-27 |
| CN101417123B (en) | 2012-06-27 |
| BRPI0804623B8 (en) | 2021-05-25 |
| NZ572131A (en) | 2010-06-25 |
| CA2641830C (en) | 2013-07-16 |
| JP2009108059A (en) | 2009-05-21 |
| US20090111740A1 (en) | 2009-04-30 |
| BRPI0804623B1 (en) | 2020-02-11 |
| UY31418A1 (en) | 2009-05-29 |
| RU2414925C2 (en) | 2011-03-27 |
| CL2008003133A1 (en) | 2009-08-07 |
| PT2111868E (en) | 2013-10-17 |
| ES2428698T3 (en) | 2013-11-08 |
| AU2008233025B8 (en) | 2013-07-25 |
| AU2008233025A1 (en) | 2009-05-14 |
| ES2332846B1 (en) | 2010-07-08 |
| EP2111868B1 (en) | 2013-08-21 |
| PL2111868T3 (en) | 2014-01-31 |
| AR068901A1 (en) | 2009-12-16 |
| US7851446B2 (en) | 2010-12-14 |
| CA2641830A1 (en) | 2009-04-26 |
| EP2111868A1 (en) | 2009-10-28 |
| CN101417123A (en) | 2009-04-29 |
| ES2332846A1 (en) | 2010-02-12 |
| JP5437619B2 (en) | 2014-03-12 |
| HK1126689A1 (en) | 2009-09-11 |
| MX2008013635A (en) | 2009-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008141076A (en) | APPLICATION OF THERAPEUTIC HUMAN ALBUMIN FOR THE PRODUCTION OF A MEDICINE FOR THE TREATMENT OF PATIENTS AFFECTING COGNITIVE DISORDERS | |
| JP2022009125A5 (en) | ||
| Tang et al. | Intranasal dexmedetomidine on stress hormones, inflammatory markers, and postoperative analgesia after functional endoscopic sinus surgery | |
| RU2015134581A (en) | NITROXIL DONORS WITH IMPROVED THERAPEUTIC INDEX | |
| JP2011512856A5 (en) | ||
| EA200700214A1 (en) | MEMANTINE AS AN ADDITIONAL THERAPY FOR ATYPICAL ANTIPSYCHOTIC REMEDIES IN PATIENTS WITH SCHIZOPHRENIA | |
| RU2012108656A (en) | APPLICATION OF 4-AMINOPYRIDINE TO IMPROVE CONDITION IN NEURO-COGNITIVE AND / OR NEUROPSYCHIATRIC DISORDERS IN PATIENTS WITH DEMILINIZING AND OTHER DISEASES OF THE NERVOUS SYSTEM | |
| CY1115269T1 (en) | USE OF COMPETITIVE OPTIONS FOR THE PREPARATION OF A MEDICINE IN THE THERAPEUTIC TREATMENT OF BUBBLE DISEASES | |
| ATE366581T1 (en) | APOPTOTIC BODY FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND OTHER NERVOUS DISEASES | |
| RU2013112890A (en) | THERAPEUTIC USE 1- [2- (2,4-DIMETHYLPHENYLSULFANIL) Phenyl] PIPERASINE | |
| NO20061515L (en) | Use of oxcarbazepine for the treatment of diabetic neurpathic pain and improvement of sleep | |
| EA200900214A1 (en) | PHARMACEUTICAL COMPOSITION OF RIFABUTIN FOR THE TREATMENT OF TUBERCULOSIS, THE WAY OF ITS OBTAINING AND THE METHOD OF TREATMENT | |
| RU2006101061A (en) | ASENAPINE FOR THE TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH OVERBODY WEIGHT OR PREPAREDNESS FOR OVERWEIGHT BODY | |
| ES2668943T3 (en) | Pharmaceutical composition to treat premature ejaculation and method of treatment of premature ejaculation | |
| RU2572504C1 (en) | Method of treating radial sialadenopathy | |
| Ghimire et al. | Propofol sedation during spinal anaesthesia-a dose finding study | |
| Megha et al. | Ayurvedic management of Pakshaghata (Cerebrovascular Accident): A case study | |
| Kovosi et al. | Administering medications for Parkinson disease on time | |
| RU2549474C1 (en) | Method for preanaesthetic medication preceding gynaecological surgeries under general anaesthesia | |
| Winter et al. | 0561 Solriamfetol Real World Experience Study: Safety, Efficacy, and Follow-Up for Patients with Obstructive Sleep Apnea in Germany | |
| Almomani | The effect of ketamine on blood pressure, heart rate, respiratory rate and intraocular pressure in patients undergoing ocular procedures | |
| Ahuja | A Comparitive Clinical Evaluation of Dexmedetomidine V/S Propofol in Patients Undergoing Extraction of Impacted Mandibular Third Molars | |
| RU2021106142A (en) | USE OF LOW-VOLUME PLASMAPHERESIS FOR THE TREATMENT OF EARLY AND MIDDLE STAGES OF ALZHEIMER'S DISEASE | |
| Lamichhane et al. | A Bipolar Lady with Sudden Neurological Complications | |
| Tang | Using lithium |